Revue des maladies respiratoires · 2003
[Acute respiratory distress syndrome due to pneumonitis following intrathecal methotrexate administration].
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Le Guillou F, Dominique S, Dubruille V, Contentin N, Tilly H, Nouvet G
Аннотация
INTRODUCTION: Methotrexate, given orally or systemically, is associated with pneumonitis in 7% of cases.
CASE REPORT: This case report describes acute respiratory distress syndrome, due to diffuse pneumonitis, in a patient with malignant non-Hodgkin's lymphoma being treated with combination chemotherapy which included doxorubicin, cyclophosphamide, bleomycin, vindesin and intrathecal methotrexate with G-CSF (filgrastine- Neupogen). The clinical course, the lack of an identifiable infectious agent and the complete response to corticosteroids suggested a drug-induced cause. After ruling out the other chemotherapy agents, methotrexate was considered to be the causal agent. The unusual feature of this case was that pneumonitis developed after intrathecal administration of methotrexate.
CONCLUSION: Methotrexate-associated respiratory complications can occur with whichever route the drug is administered.
CASE REPORT: This case report describes acute respiratory distress syndrome, due to diffuse pneumonitis, in a patient with malignant non-Hodgkin's lymphoma being treated with combination chemotherapy which included doxorubicin, cyclophosphamide, bleomycin, vindesin and intrathecal methotrexate with G-CSF (filgrastine- Neupogen). The clinical course, the lack of an identifiable infectious agent and the complete response to corticosteroids suggested a drug-induced cause. After ruling out the other chemotherapy agents, methotrexate was considered to be the causal agent. The unusual feature of this case was that pneumonitis developed after intrathecal administration of methotrexate.
CONCLUSION: Methotrexate-associated respiratory complications can occur with whichever route the drug is administered.
Предметные рубрики MeSH
Anti-Inflammatory AgentsAntimetabolites, AntineoplasticAntineoplastic Agents, AlkylatingAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBleomycinBronchoalveolar Lavage FluidBronchoscopyCyclophosphamideDoxorubicinFilgrastimGranulocyte Colony-Stimulating FactorHumansInjections, SpinalLeukocyte CountLymphoma, Non-HodgkinMaleMethotrexateMiddle AgedPneumoniaRecombinant ProteinsRespiratory Distress SyndromeSteroidsTomography, X-Ray ComputedVindesine